Clinical Trials Browser

Phase 2 × Mesothelioma, Malignant × Everolimus × Clear all

NCT01024946 2015-05-12

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

Phase 2 Completed

11 enrolled 6 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma